Dupilumab efficacy and safety in moderate-to-severe uncontrolled Asthma

Dupilumab is a fully human anti-interleukin-4 receptor α monoclonal antibody that blocks both interleukin-4 and interleukin-13 signaling. We assessed its efficacy and safety in patients with uncontrolled asthma.We randomly assigned 1902 patients 12 years of age or older with uncontrolled asthma in a...

Full description

Bibliographic Details
Main Authors:	Castro, M, Corren, J, Pavord, I, Maspero, J, Wenzel, S, Rabe, K, Busse, W, Ford, L, Sher, L, FitzGerald, J, Katelaris, C, Tohda, Y, Zhang, B, Staudinger, H, Pirozzi, G, Amin, N, Ruddy, M, Akinlade, B, Khan, A, Chao, J, Martincova, R, Graham, N, Hamilton, J, Swanson, B, Stahl, N, Yancopoulos, G, Teper, A
Format:	Journal article
Language:	English
Published:	Massachusetts Medical Society 2018

Dupilumab efficacy and safety in moderate-to-severe uncontrolled Asthma

Similar Items